Společnost Biosidus rozšiřuje výrobní kapacitu biologických léčiv a posiluje globální dodavatelské kapacity pro agalsidázu beta

agalsidase betaPositive

AI Analysis

Summary

Biosidus announced the commissioning of a new bioreactor facility in Argentina to expand manufacturing capacity and strengthen global supply capabilities for agalsidase beta biosimilar.

Importance:3/10

Sentiment:

0.60

manufacturing expansionbiosimilarcapacity increasesupply chainbioreactor

Read the original article

Published by PR Newswire Clinical Trials on August 27, 2026 8:58 AM

Read Original